Neither drug is clearly better. The choice must be tailored to each patient.
In the urgent space between consciousness and the breathing tube, clinicians have long sought certainty where medicine offers only trade-offs. A large American multicenter trial enrolling 2,365 critically ill adults compared ketamine and etomidate for rapid sequence intubation, hoping to resolve a debate that has shaped emergency and intensive care practice for years. The study found equivalent 28-day mortality between the two drugs, yet revealed that ketamine carries a meaningfully higher risk of immediate cardiovascular collapse — particularly in the sickest patients. The question of which drug is better remains open, replaced now by the harder wisdom that the answer depends on the patient in front of you.
- For years, clinicians have chosen between two imperfect drugs under pressure, with etomidate's hemodynamic steadiness shadowed by fears of increased mortality and ketamine's theoretical cardiovascular protection undermined by real-world instability.
- The largest randomized trial yet on this question enrolled 2,365 critically ill adults across 14 US sites, tracking death and cardiovascular collapse in the critical minutes and days following intubation.
- Mortality landed nearly identically — 28.1% for ketamine, 29.1% for etomidate — but ketamine triggered cardiovascular collapse at a rate of 22% versus 17%, a gap that widened sharply among septic and severely ill patients.
- The instability ketamine caused demanded more aggressive intervention in the immediate aftermath of intubation, yet did not translate into more deaths within 28 days — a paradox the study could not fully explain.
- With doses unstandardized, trauma patients excluded, and earlier fears about etomidate neither confirmed nor dispelled, the trial settled less than it hoped, leaving specialists to call for individualized clinical judgment rather than a universal protocol.
When a critically ill patient needs an airway secured in minutes, the clinician must choose a drug to induce unconsciousness — and for years, that choice has carried no clean answer. Ketamine and etomidate both work fast enough for rapid sequence intubation, but each carries a different profile of risk and reassurance. A large randomized trial across 14 American emergency departments and intensive care units set out to resolve the debate. It found something more complicated than resolution.
Researchers assigned 1,176 patients to ketamine and 1,189 to etomidate, then followed them for 28 days. The mortality figures were nearly indistinguishable — 28.1% and 29.1% respectively — suggesting the drugs are equivalent by the measure that matters most. But cardiovascular collapse, defined as a dangerous blood pressure drop or the urgent need for vasopressors within two minutes of intubation, told a different story. Ketamine triggered it in 22% of patients versus 17% for etomidate. Among those with sepsis, the gap reached 30.6% versus 20.9%. In the sickest patients by APACHE II score, it stretched further still.
The paradox at the heart of the findings is that ketamine destabilized patients more often in the critical minutes after intubation — requiring more aggressive support — yet did not kill more of them within 28 days. Whether that instability carries consequences beyond the study window remains unknown.
Etomidate's reputation has long been complicated by observational studies suggesting it may increase mortality risk, a fear that this trial neither confirmed nor erased. Its hemodynamic steadiness in the moment still comes with lingering unease. Ketamine's cardiovascular instability, meanwhile, demands closer monitoring and readiness to intervene immediately after the tube is placed.
What the study ultimately produced was not a winner but a clearer map of each drug's dangers. Specialists now emphasize that the choice must be shaped by the individual patient — their diagnosis, their fragility, their specific risks. The controversy endures, and so does the weight of deciding between two medicines that are, in their own ways, imperfect.
When a critically ill patient needs a breathing tube placed quickly, anesthesiologists face a choice that has no clear answer. Should they use ketamine or etomidate? Both drugs can induce unconsciousness fast enough for rapid sequence intubation—the procedure of putting a patient under and securing an airway in minutes. But which one keeps the patient safer? A large randomized study involving 2,365 critically ill adults across 14 emergency departments and intensive care units in the United States set out to settle the question. It did not.
The two drugs have competing advantages that have made this decision fraught for years. Etomidate is known for its hemodynamic stability—it doesn't cause wild swings in blood pressure or heart function, which seems like an obvious win for a patient already on the edge. Ketamine, by contrast, has protective properties for the cardiovascular system, theoretically shielding the heart and vessels from collapse. Yet some observational studies have whispered that etomidate might actually increase the risk of death, a shadow that has hung over its use despite its steadiness in the moment.
Researchers enrolled 1,176 patients to receive ketamine and 1,189 to receive etomidate, then tracked what happened over the next 28 days. They looked at who died and who experienced cardiovascular collapse—defined as a systolic blood pressure dropping below 65 millimeters of mercury or requiring vasopressors to be started or increased within two minutes of intubation. The mortality numbers came back nearly identical: 28.1 percent in the ketamine group, 29.1 percent in the etomidate group. No meaningful difference. The drugs, at least by this measure, were equivalent.
But the story did not end there. Cardiovascular collapse happened more often in patients given ketamine—22 percent versus 17 percent. The gap widened in sicker patients. Among those with sepsis, ketamine patients experienced cardiovascular collapse at a rate of 30.6 percent compared to 20.9 percent for etomidate. In patients with an APACHE II score above 20, indicating severe illness, the disparity was even starker: 31.4 percent versus 20.7 percent. Technical complications and low oxygen levels showed no difference between the two drugs.
This is where the study's findings became complicated. The data suggested that while both drugs killed patients at roughly the same rate, ketamine seemed to destabilize the cardiovascular system more often in the immediate aftermath of intubation. That instability required more intervention—more vasopressors, more aggressive support. Yet it did not translate into more deaths, at least not within 28 days.
The American College of Critical Care Medicine's guidelines currently state there is no meaningful difference between the two drugs for this procedure. But specialists remain skeptical of etomidate, haunted by earlier observational studies suggesting it increases mortality risk. The new randomized evidence did not confirm that fear, yet it also did not dispel it. The study had limitations: doses were not standardized, different clinicians performed procedures differently, and trauma patients were excluded from the analysis.
What emerged instead was a more unsettling conclusion: neither drug is clearly better. Ketamine's hemodynamic instability means clinicians need to watch patients more closely in the minutes after intubation, ready to support blood pressure aggressively. Etomidate's steadiness in the moment comes with a lingering unease about long-term outcomes that this study could not resolve. The choice, specialists now say, must be tailored to each patient—their illness, their stability, their risk factors. The controversy remains, and so does the weight of deciding between two imperfect options.
Notable Quotes
The American College of Critical Care Medicine currently states there is no meaningful difference between the two drugs for rapid sequence intubation— Clinical guidelines
Specialists continue favoring caution with etomidate despite equivalent mortality findings, citing earlier observational studies suggesting increased mortality risk— Clinical practice consensus
The Hearth Conversation Another angle on the story
So after studying 2,365 patients, they found the drugs kill people at the same rate. Why does anyone care which one you use?
Because mortality is only part of the story. Ketamine destabilizes blood pressure in the immediate aftermath—22 percent of patients versus 17 percent with etomidate. That's real, even if it doesn't kill more people in 28 days.
But if it doesn't kill more people, isn't that what matters?
In theory, yes. But in practice, a patient whose blood pressure crashes after intubation needs emergency intervention. That's stressful, it's risky, and it might have consequences the study didn't measure.
So etomidate is safer then?
Not necessarily. Older studies suggested etomidate increases mortality, which is why many doctors avoid it despite this new evidence. The study couldn't resolve that fear.
What would resolve it?
Honestly, probably nothing short of a much larger study over a longer time period, with standardized dosing and procedures. But that's expensive and difficult. So clinicians are left choosing based on the individual patient in front of them.
Which means the controversy stays.
It does. And that's actually the most honest answer the study gives.